Cite
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
MLA
Makker, V., et al. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376721298&authtype=sso&custid=ns315887.
APA
Makker, V., Colombo, N., Herráez, A., Monk, B., Mackay, H., Santin, A., Miller, D., Moore, R., Baron-Hay, S., Ray-Coquard, I., Ushijima, K., Yonemori, K., Kim, Y., Guerra Alia, E., Sanli, U., Bird, S., Orlowski, R., Mckenzie, J., Okpara, C., … Lorusso, D. (2023). Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
Chicago
Makker, V, N Colombo, A Herráez, B Monk, H Mackay, A Santin, D Miller, et al. 2023. “Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376721298&authtype=sso&custid=ns315887.